SynDermix AG

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
SynDermix AG (SDX) is a Swiss developer of innovative health technologies that focuses on ground-breaking therapies, which address patient convenience (with efficacy and safety) in areas of major unmet medical need. Its mission is to enter into strategic partnerships for the acquisition, development and commercialisation of a robust portfolio of assets that are consistent with the vision of SDX.

SDX holds intellectual property in three technology platforms: Bioelesonic, nitric oxide (NO) and plant lectins, whose applications cover a wide range of therapeutic areas, including rare diseases, wound-healing, respiratory and CNS. These platforms provide the scientific basis for SDX’s current pipeline of connected medical devices that provide drug-free, non-invasive medical interventions (with SDX-3101 from the Bioelesonic platform being the most advanced asset), and of preclinical stage topical drugs that leverage compounds of natural origin, from the NO and plant lectins platforms.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Switzerland
Year Founded:
2009
Main Therapeutic Focus:
Lead Product in Development:
SDX-3101 medical device for the treatment of chronic rhinosinusitis without nasal polyps
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
Designated Managing Director
SynDermix AG